Under Trump, FDA seeks to abandon expert reviews of new drugs
The FDA under the leadership of President Trump is considering a major policy change that would eliminate the use of outside experts to review drug applications. This move has raised concerns among critics who believe it could lead to less transparency and accountability in the agency’s decision-making process.
George Tidmarsh, the head of the FDA’s Center for Drug Evaluation and Research, stated that the agency is looking to move away from convening panels of experts to review individual drugs, as he believes they are unnecessary and redundant. He mentioned that these advisory meetings require a significant amount of work for both the companies and the FDA, and he would rather focus on broader issues.
The FDA’s advisory committees were established in 1972 to provide expert advice on technical decisions related to drug approvals. These committees play a crucial role in reviewing evidence and voting on whether the FDA should approve drugs, vaccines, and medical devices. However, recent decisions by the FDA, such as the approval of the controversial drug Aduhelm for Alzheimer’s disease, have highlighted the agency’s struggle to balance industry pressure and patient needs with rigorous evaluation standards.
While Tidmarsh believes that advisory committee meetings on specific drugs are unnecessary in light of the agency’s publication of complete response letters, former FDA officials and experts disagree. They argue that these meetings help FDA scientists make informed decisions and increase public understanding of the drug regulation process.
Critics of the proposed policy change point out that advisory committees provide valuable insights and perspectives that the FDA may not consider on its own. They emphasize the importance of public input and scrutiny in the drug approval process.
Despite the potential implications of this policy shift, the FDA has already reduced the number of advisory committee meetings under the current administration. Instead, FDA Commissioner Marty Makary has opted for handpicked panels of scientists who align with his views on specific issues like hormone replacement therapy and antidepressants.
The decision to move away from advisory committees has sparked concerns about the FDA consolidating power and reducing accountability to external experts and the public. It remains to be seen how this shift will impact the agency’s decision-making process and the transparency of its regulatory actions.
In conclusion, the debate over the role of advisory committees in drug approvals underscores the need for a balance between expert input, public engagement, and regulatory efficiency within the FDA. The outcome of this policy change could have far-reaching implications for the future of drug regulation in the United States.
